Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

Por Xu, Y., Kolesar, J. M., Schaaf, L. J., Drengler, R., Duan, W., Otterson, G., Shapiro, C., Kuhn, J., Villalona-Calero, M. A.
Publicado em 2008

A Phase I Study of an Oral Simulated FOLFOX with High Dose Capecitabine

Por Mulkerin, D., LoConte, N.K., Holen, K.D., Thomas, J.P., Alberti, D., Marnocha, R., Kolesar, J., Eickhoff, J., Oliver, K., Feierabend, C., Wilding, G.
Publicado em 2009

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Por Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., Gordon, L. I.
Publicado em 2013

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Por Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., Gordon, L. I.
Publicado no Ann Oncol (2014)

Genotypes of NK cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy: A Children’s Oncology Group Report

Por Delgado, DC, Hank, JA, Kolesar, J, Lorentzen, D, Gan, J, Seo, S, Kim, KM, Shusterman, S, Gillies, SD, Reisfeld, RA, Yang, R, Gadbaw, B, DeSantes, KD, London, WB, Seeger, RC, Maris, JM, Sondel, PM
Publicado em 2010